The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors

The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors

We sought to identify fibroblast growth factor receptor 2 (FGFR2) kinase domain mutations that confer resistance to the pan-FGFR inhibitor, dovitinib, and explore the mechanism of action of the drug-resistant mutations. We cultured BaF3 cells overexpressing FGFR2 in high concentrations of dovitinib...

Full description

Bibliographic Details
Main Authors: Sara A Byron, Huaibin Chen, Andreas Wortmann, David Loch, Michael G Gartside, Farhad Dehkhoda, Steven P Blais, Thomas A Neubert, Moosa Mohammadi, Pamela M Pollock
Format: Article
Language:English
Published: Elsevier 2013-08-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558613801017

Internet

http://www.sciencedirect.com/science/article/pii/S1476558613801017

Similar Items